BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:zenagamtide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of zenagamtide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07535307-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07535307)
DESCRIPTION:zenagamtide\, phase 1\, Type 2 Diabetes.\nStudy: Investigating 
 How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes\nEstimat
 ed primary completion: 11 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07535307
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587710-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07587710)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study Looki
 ng Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well
  it is Tolerated in People With Reduced Liver Function and Normal Liver Fu
 nction\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07587710
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944118-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280114
DTEND;VALUE=DATE:20280115
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07944118)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: Examination of How the
  Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect t
 he Amount of Food Left in the Stomach in Adults With Overweight or Obesity
 \, With or Without Type 2 Diabetes\nEstimated primary completion: 14 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0794
 4118
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508020-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07508020)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study Looki
 ng at How NNC0487-0111 Affects Food Intake\, Appetite and Metabolism After
  Meals in People With Obesity\nEstimated primary completion: 19 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07508020
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931495-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931495)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes Treated With Diet and Ex
 ercise\nEstimated primary completion: 5 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07931495
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503210-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07503210)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 12: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People With Ex
 cess Body Weight Maintain Their Weight Loss\nEstimated primary completion:
  6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagam
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07503210
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815067-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07815067)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study Looki
 ng at the Effect of Timing of Meal After Dosing and Water Volume at Dosing
  on How the Medicine Zenagamtide is Taken up by the Body of Participants W
 ith Overweight or Obesity\nEstimated primary completion: 12 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07815067
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571109-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571109)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 4: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway 
 Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary completio
 n: 26 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zena
 gamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07571109
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720271-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07720271)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 9: A Research St
 udy Investigating How Well Zenagamtide Tablets Help People With Excess Bod
 y Weight Lose Weight\nEstimated primary completion: 27 June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07720271
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931573-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931573)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 3: A 
 Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lo
 wers Blood Sugar and Body Weight Compared to Semaglutide in People With Ty
 pe 2 Diabetes Treated With Metformin\, SGLT2i\, or Both\nEstimated primary
  completion: 4 July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07931573
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571005-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280712
DTEND;VALUE=DATE:20280713
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571005)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 3: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Air
 way Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary compl
 etion: 12 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07571005
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931599-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931599)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Su
 gar and Body Weight Compared to Semaglutide at Lower Dose Levels in People
  With Type 2 Diabetes Treated With Metformin\, Sodium-Glucose Cotransporte
 r 2 Inhibitors (SGLT2i)\, or Both\nEstimated primary completion: 24 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07931599
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797335-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07797335)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 7: A 
 Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and B
 ody Weight Compared to Insulin Glargine in People With Type 2 Diabetes and
  Increased Risk of Diseases That Affect the Heart and Blood Vessels Treate
 d With 1-3 Other Diabetes Medications\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 7335
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931547-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931547)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disea
 se Treated With Once Daily Basal Insulin Alone or in Combination With Metf
 ormin\, SGLT2i\, or Both\nEstimated primary completion: 31 July 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07931547
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533175-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07533175)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 2: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Type 2 Diabetes Lose Weight\nEstimated primary complet
 ion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 enagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07533175
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481630-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07481630)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine NNC0487-0111 Helps People With Excess Body 
 Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstimated prim
 ary completion: 14 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07481630
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509307-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07509307)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 6: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstim
 ated primary completion: 14 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07509307
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855133-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280906
DTEND;VALUE=DATE:20280907
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07855133)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study Inves
 tigating How Adults With Overweight or Obesity\, With or Without Type 2 Di
 abetes\, Tolerate Switching to a New Treatment (Zenagamtide) From Their Cu
 rrent Semaglutide Medication\nEstimated primary completion: 6 September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07855133
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868354-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07868354)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study Inves
 tigating How Adults With Overweight or Obesity\, With or Without Type 2 Di
 abetes\, Tolerate Switching to a New Treatment (Zenagamtide) From Their Cu
 rrent Tirzepatide Medication\nEstimated primary completion: 7 September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07868354
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757087-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280918
DTEND;VALUE=DATE:20280919
SUMMARY:zenagamtide: Phase 1 readout est. (NCT07757087)
DESCRIPTION:zenagamtide\, phase 1\, Obesity.\nStudy: A Research Study to Se
 e How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Ad
 ults Living With Overweight or Obesity\, Compared to a Low-calorie Diet or
  Placebo\nEstimated primary completion: 18 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07757087
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668414-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668414)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine Zenagamtide Helps People With Excess Body W
 eight Lose Weight Compared to Semaglutide\nEstimated primary completion: 1
 0 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenag
 amtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07668414
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400107-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07400107)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 8: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Compared to Semagluti
 de Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight\nE
 stimated primary completion: 19 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07400107
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668401-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668401)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 13: A Research S
 tudy Investigating How Well the Medicine Zenagamtide Helps People in Asia 
 With Excess Body Weight Lose Weight\nEstimated primary completion: 11 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 68401
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822061-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20290205
DTEND;VALUE=DATE:20290206
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07822061)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 10: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People in Japa
 n With Excess Body Weight Lose Weight\nEstimated primary completion: 5 Feb
 ruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7822061
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339423-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07339423)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 1: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight Lose Weight\nEstimated primary completion: 26 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07339423
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567001-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07567001)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well NNC0487-0111 Works Compared to Placebo in People With Heart
  Failure and Obesity\nEstimated primary completion: 23 July 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07567001
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861100-133@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20300916
DTEND;VALUE=DATE:20300917
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07861100)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well Zenagamtide Works Compared to Placebo in People With Establ
 ished Atherosclerotic Cardiovascular Disease and Either Overweight or Obes
 ity\nEstimated primary completion: 16 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07861100
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
